| Literature DB >> 32294407 |
Eslam Mohamed1, Rosa A Sierra1, Jimena Trillo-Tinoco2, Yu Cao1, Patrick Innamarato1, Kyle K Payne1, Alvaro de Mingo Pulido1, Jessica Mandula1, Shuzhong Zhang3, Paul Thevenot4, Subir Biswas1, Sarah K Abdalla1, Tara Lee Costich1, Kay Hänggi1, Carmen M Anadon1, Elsa R Flores5, Eric B Haura5, Shikhar Mehrotra6, Shari Pilon-Thomas1, Brian Ruffell1, David H Munn7, Juan R Cubillos-Ruiz8, Jose R Conejo-Garcia1, Paulo C Rodriguez9.
Abstract
The primary mechanisms supporting immunoregulatory polarization of myeloid cells upon infiltration into tumors remain largely unexplored. Elucidation of these signals could enable better strategies to restore protective anti-tumor immunity. Here, we investigated the role of the intrinsic activation of the PKR-like endoplasmic reticulum (ER) kinase (PERK) in the immunoinhibitory actions of tumor-associated myeloid-derived suppressor cells (tumor-MDSCs). PERK signaling increased in tumor-MDSCs, and its deletion transformed MDSCs into myeloid cells that activated CD8+ T cell-mediated immunity against cancer. Tumor-MDSCs lacking PERK exhibited disrupted NRF2-driven antioxidant capacity and impaired mitochondrial respiratory homeostasis. Moreover, reduced NRF2 signaling in PERK-deficient MDSCs elicited cytosolic mitochondrial DNA elevation and, consequently, STING-dependent expression of anti-tumor type I interferon. Reactivation of NRF2 signaling, conditional deletion of STING, or blockade of type I interferon receptor I restored the immunoinhibitory potential of PERK-ablated MDSCs. Our findings demonstrate the pivotal role of PERK in tumor-MDSC functionality and unveil strategies to reprogram immunosuppressive myelopoiesis in tumors to boost cancer immunotherapy.Entities:
Keywords: ER stress; MDSCs; NRF2; PERK; STING; tumor immunity; type I IFN; unfolded protein responses
Mesh:
Substances:
Year: 2020 PMID: 32294407 PMCID: PMC7207019 DOI: 10.1016/j.immuni.2020.03.004
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745